Tag Archive for: ophthalmology

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

/in

Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces […]

Read more

Breye Therapeutics Strengthens Management Team and Launches Website

/in

Last week, our client Breye Therapeutics announced the appointment of Dr Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors. It also launched its new website and LinkedIn page. Breye is a clinical-stage biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of […]

Read more

Breye Therapeutics Strengthens Management Team and Board

/in

Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer Dr. Gabriela Burian, MD appointed to the Board of Directors Copenhagen, Denmark, 20 April 2023 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific […]

Read more